Cargando…
Randomized controlled clinical trial of a combination therapy of vildagliptin plus an α-glucosidase inhibitor for patients with type II diabetes mellitus
The aim of this study was to assess the efficacy of a combination therapy of vildagliptin plus an α-glucosidase inhibitor for patients with type II diabetes mellitus. Type II diabetic patients exhibiting poor glycemic control following α-glucosidase inhibitor treatment for at least two months were s...
Autores principales: | SU, YONG, SU, YA-LI, LV, LI-FANG, WANG, LI-MIN, LI, QUAN-ZHONG, ZHAO, ZHI-GANG |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4043567/ https://www.ncbi.nlm.nih.gov/pubmed/24926379 http://dx.doi.org/10.3892/etm.2014.1637 |
Ejemplares similares
-
A randomized controlled clinical trial of vildagliptin plus metformin combination therapy in patients with type II diabetes mellitus
por: SU, YONG, et al.
Publicado: (2014) -
Data on vildagliptin and vildagliptin plus metformin combination in type-2 diabetes mellitus management
por: Das, Sambit, et al.
Publicado: (2021) -
Vildagliptin Versus α-Glucosidase Inhibitor as Add-On to Metformin for Type 2 Diabetes: Subgroup Analysis of the China Prospective Diabetes Study
por: Chen, Yulong, et al.
Publicado: (2019) -
Efficacy and safety of nateglinide plus vildagliptin combination therapy compared with switching to vildagliptin in type 2 diabetes patients inadequately controlled with nateglinide
por: Kudo‐Fujimaki, Kyoko, et al.
Publicado: (2013) -
Momilactones A and B Are α-Amylase and α-Glucosidase Inhibitors
por: Quan, Nguyen Van, et al.
Publicado: (2019)